Insmed Financial Results
Insmed reported third-quarter 2026 total revenues of $524.4 million, driven by strong commercial momentum for BRINSUPRI and ARIKAYCE. The company raised its full-year 2026 revenue guidance for both products following the successful launch of BRINSUPRI in Japan and continued growth in the U.S. market.
“The third quarter marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipeline. BRINSUPRI’s U.S. launch continues to exceed expectations and ARIKAYCE continues to grow while in its ninth year on the market. This performance supports our decision to raise the low end of our full-year 2026 revenue guidance for both products.”
Will Lewis, Chair and Chief Executive Officer of Insmed